PC-3 Xenograft Model Service for Prostate Cancer

The PC-3 cell line provides a highly aggressive and clinically relevant in vivo platform for investigating androgen-independent prostate cancer and metastatic progression. As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision PC-3 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your prostate cancer drug discovery and development pipeline.

Overview of PC-3 Xenograft Model for Prostate Cancer

The PC-3 xenograft model is an essential in vivo translational system utilized in oncology research for the study of advanced, androgen-independent prostate carcinoma. By transplanting human PC-3 cells into immunodeficient rodent hosts, this model effectively reproduces the solid tumor growth characteristics, high metastatic potential, and invasive patterns typical of human high-grade prostate malignancies.

Biologically, the PC-3 model is highly valued for its complete lack of androgen receptor (AR) expression and low levels of prostate-specific antigen (PSA), which makes it an ideal system for evaluating the efficacy of therapies targeting androgen-independent pathways and signaling mechanisms associated with metastatic disease. The model maintains critical phenotypic features of advanced carcinoma, demonstrating rapid, reproducible tumor formation and significant responsiveness to a variety of cytotoxic and targeted pharmacological agents in an in vivo environment. Consequently, the PC-3 model is extensively deployed in pre-clinical screening programs to assess the anti-tumor and anti-metastatic potency of novel therapeutic candidates.

Fig 1. SLC25A10 promotes PCa cells proliferation, apoptosis, and invasiveness. (Yu G, et al., 2025)

Cell Line Information: PC-3

The PC-3 cell line is derived from a metastatic site (bone) of human prostate carcinoma. These cells exhibit stable, aggressive, and androgen-independent growth characteristics in vitro, making them a preferred choice for studying the behaviors and therapeutic sensitivities of advanced pre-clinical prostate cancer models.

Our Services

Workflow of PC-3 Xenograft Model Construction

• Cell Culture & Quality Control: Human PC-3 cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient rodent models are utilized for tumor engraftment, with all animals maintained in a controlled, pathogen-free environment to ensure physiological stability and consistency throughout the study.
• Precision Inoculation: A calibrated suspension of high-viability PC-3 cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take efficiency. Cells are inoculated in vivo via subcutaneous injection into the host flank to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor size is measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into matched cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. PC-3 Xenograft Model Construction Workflow

Case Study - PC-3 Xenograft Model Development

A pre-clinical validation study was conducted using the PC-3 xenograft model to evaluate the therapeutic efficacy of a novel small-molecule inhibitor targeting invasive prostate carcinoma. Following the successful subcutaneous inoculation of PC-3 cells into immunodeficient mice, the host animals developed firm, rapidly expanding solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's high sensitivity and predictive reliability for screening novel interventions against advanced prostate cancer.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing specialized prostate cancer lineages, providing highly reproducible in vivo translational platforms for complex hormonal-resistance research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your prostate cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our PC-3 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.